Drug intelligence / Profile preview

semaglutide biosimilar (HDG1901)

Development stage: Phase 3
Lead developer: Hangzhou Zhongmei Huadong Pharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

HDG1901 is a biosimilar of semaglutide, developed by Hangzhou Zhongmei Huadong Pharmaceutical and Chongqing Peg-Bio Biopharma. It is a recombinant polypeptide that acts as an agonist of the glucagon-like peptide 1 receptor (GLP-1R). The drug is administered via subcutaneous injection and is being developed primarily for the treatment of type 2 diabetes mellitus, with additional potential in obesity. As a GLP-1 receptor agonist, its mechanism mimics endogenous incretin hormones to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite[4][9]. Clinical trials are ongoing to establish pharmacokinetic similarity and therapeutic equivalence to Ozempic (semaglutide)[3][5].

Other names: semaglutide biosimilar (Huadong Medicine/Chongqing Peg-Bio Biopharma)司美格鲁肽生物类似药（Chongqing Paijin Biotechnology Co Ltd.）

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on semaglutide biosimilar (HDG1901).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on semaglutide biosimilar (HDG1901).

Explore the full profile